Elly Barry
NGM Biopharmaceuticals (United States)(US)
Publications by Year
Research Areas
Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, Childhood Cancer Survivors' Quality of Life, Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial(2010)444 cited
- → Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management(2007)309 cited
- → Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols(2007)192 cited
- → Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia(2011)122 cited
- → Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane(2008)118 cited
- → A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia(2009)85 cited
- → ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients(2020)66 cited
- → Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation(2008)59 cited
- → Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias(2017)53 cited
- → Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin(2007)51 cited